


Picroside I

Cat. No.:	HY-N0407
CAS No.:	27409-30-9
Molecular Formula:	C ₂₄ H ₂₈ O ₁₁
Molecular Weight:	492.47
Target:	STAT
Pathway:	JAK/STAT Signaling; Stem Cell/Wnt
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (507.65 mM; Need ultrasonic) H ₂ O : 116.67 mg/mL (236.91 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	2.0306 mL	10.1529 mL	20.3058 mL
				5 mM	0.4061 mL	2.0306 mL	4.0612 mL
				10 mM	0.2031 mL	1.0153 mL	2.0306 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: PBS Solubility: 12.5 mg/mL (25.38 mM); Clear solution; Need ultrasonic						

BIOLOGICAL ACTIVITY

Description	Picroside I is the major ingredient of <i>Picrorhiza scrophulariiflora</i> . <i>Picrorhiza scrophulariiflora</i> is a high value medicinal herb due to rich source of hepatoprotective metabolites, Picroside-I and Picroside-II ^[1] . Picroside I is a promising agent for the management of asthma. Picroside I reduces the inflammation significantly at its higher dose. Picroside I also downregulates pSTAT6 and GATA3 expressions. Picroside I dose-dependently increases the serum levels of IFN- γ ^[2] .	
IC ₅₀ & Target	STAT6	
In Vivo	Picroside I (20 mg/kg, o.p, 12 d) reduces AHR in the experimental asthma model and reduces OVA-associated IgE levels ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Ovalbumin (OVA) systematic sensitization BALB/c mice model ^[2]

Dosage:	0.2, 2.0 and 20 mg/kg
Administration:	Orally, once daily, from day 20 to day 32
Result:	Inhibited allergen-triggered inflammatory cell infiltration.

REFERENCES

- [1]. Ganeshkumar Y, et al. Picroside I and Picroside II from Tissue Cultures of Picrorhiza kurroa. Pharmacognosy Res. 2017 Dec;9(Suppl 1):S53-S56.
- [2]. Sen Zhang, et al. Picroside I inhibits asthma phenotypes by regulating Tbet/GATA-3 ratio and Th1/Th2 balance in a murine model of asthma. Tropical Journal of Pharmaceutical Research September 2018; 17 (9): 1777-1782.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA